Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Arix Bioscience Plc LSE:ARIX London Ordinary Share GB00BD045071 ORD 0.001P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50 -0.46% 108.50 108.00 109.00 109.00 108.50 109.00 20,011 08:37:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.3 -61.1 -48.0 - 140

Corporate update from portfolio company Harpoon Therapeutics

14/03/2022 11:32am

UK Regulatory (RNS & others)

Arix Bioscience (LSE:ARIX)
Historical Stock Chart

From Sep 2021 to Sep 2022

Click Here for more Arix Bioscience Charts.

Arix Bioscience PLC (ARIX) Corporate update from portfolio company Harpoon Therapeutics 14-March-2022 / 11:32 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.



Arix Bioscience plc

Corporate update from portfolio company Harpoon Therapeutics

LONDON, 14 March 2022: Arix Bioscience plc ("Arix", LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, notes the recent announcement from Harpoon Therapeutics, Inc. (Nasdaq: HARP) of its financial results for the fourth quarter and full year of 2021, in which the company provided a corporate update.

Following a thorough analysis of its HPN424 data, including clinical results to date, the company decided to discontinue the phase 1/2 dose escalation study for HPN424 in patients with metastatic castration-resistant prostate cancer. The discontinuation will allow Harpoon to concentrate on HNP328, in development for tumours associated with delta like ligand 3 (DLL3) expression, and HPN 217 for BCMA.

Earlier in March, Harpoon announced the granting of Orphan Drug Designation for HPN328 in small cell lung cancer and Fast Track designation for HPN2178 in relapsed, refractory multiple myeloma. Studies to determine the recommended phase 2 dose for both candidates are expected to complete this year.

The full text of the Harpoon announcement can be accessed here.


For more information on Arix, please contact:

Arix Bioscience plc

+44 (0)20 7290 1050

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil

+44 (0)20 7250 1446

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.


ISIN:           GB00BD045071 
Category Code:  PFU 
TIDM:           ARIX 
LEI Code:       213800OVT3AHQCXNIX43 
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State 
Sequence No.:   148920 
EQS News ID:    1301829 
End of Announcement  EQS News Service 

Image link:


(END) Dow Jones Newswires

March 14, 2022 07:32 ET (11:32 GMT)

1 Year Arix Bioscience Chart

1 Year Arix Bioscience Chart

1 Month Arix Bioscience Chart

1 Month Arix Bioscience Chart
ADVFN Advertorial
Your Recent History
Arix Biosc..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220929 08:20:54